| Today’s Big NewsAug 18, 2023 |
| By Max Bayer BlueRock Therapeutics is laying off about 50 employees across three sites amid shifting priorities in the pipeline. The company says it's focusing on four assets out of a pipeline of nine. |
|
|
|
By James Waldron A month after unveiling a pair of phase 3 trial fails that ended hopes for Kodiak Science’s lead eye drug and sent its stock on a steep decline, the biotech’s chief medical officer will be moving on. |
By Max Bayer,Gabrielle Masson Three Flagship Pioneering-founded biotechs made key exec appointments this week, including a new CEO at Ampersand. A former Novartis cell and gene therapy leader has been tapped to lead Resolution. Cidara calls on Genentech oncology director to lead translational science. |
By Angus Liu It was only last spring that Biogen started layoffs that eventually shrank the company’s headcount by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 positions has kicked off at the struggling drugmaker. At the same time, Biogen is spending $7.3 billion to buy rare disease specialist Reata Pharmaceuticals. |
By Kevin Dunleavy Vexed by plummeting demand for their shots, COVID-19 vaccine producers are anxiously awaiting the fall inoculation season to get a glimpse of the post-pandemic market landscape. Thursday, Moderna presented preliminary data from a clinical trial of its updated mRNA shot, showing that it generates a robust response against currently circulating variants. |
By Fraiser Kansteiner Novartis’ Sandoz spinoff is right around the corner, and to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme. |
By Frank Diamond Blue Shield of California hopes to cut prescription drugs costs between 10% and 15%, or about $500 million a year, with an ambitious program that sidesteps the pharmacy benefit manager. |
By Teresa Carey,Ben Adams,Ayla Ellison,Zoey Becker,Kevin Dunleavy This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
By Angus Liu J&J and Legend Biotech's Carvykti kept growing despite a newly launched off-the-shelf option. Novo Holdings joined a $290 million investment in a Chinese R&D product and service provider. China is stressing biotech as a “major focus” as the country tries to woo foreign investment. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
October 16-17 | Boston, MA Examine the ways the IRA has impacted the drug pricing and access landscape and review business implications for affordability and evaluate strategies for engaging with stakeholders. Secure your spot today and save $400 on registration. Savings end August 21st!
|
|
| Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| |
|
